Published 16 August 2026 · Reviewed by Dr Sin Yong
Most people arrive having decided they have sensitive skin. They have tried gentler cleansers, then gentler ones again, and the redness is still there. That is usually the first clue that it is something else.
Sensitive skin describes reactivity — to a product, to weather, to friction. It is a description of behaviour.
Rosacea is a chronic inflammatory condition of the central facial skin, involving both the blood vessels and the immune response. It has a characteristic distribution: cheeks, nose, chin, central forehead. It has a course, with flares and quieter periods. And it does not resolve by removing an irritant, because the driver is not external.
“Rosacea is not sensitive skin that got worse. It is a different condition, and treating it as sensitivity is why people spend years switching cleansers while the inflammation continues underneath.”
Dr Sin YongOn the commonest misdiagnosis
Erythematotelangiectatic — persistent central redness with visible vessels. Flushing is often the earliest symptom, long before anything is fixed.
Papulopustular — inflammatory papules and pustules on a background of redness. This is the subtype most often mistaken for acne, and the distinguishing feature is what is absent: no comedones. No blackheads, no whiteheads. If someone has been treating you for adult acne and nothing has shifted, this is worth raising.
Phymatous — thickening of the skin with enlargement of the sebaceous glands, most commonly at the nose. It develops gradually and is more common in men.
Ocular — dryness, grittiness, irritation and lid margin inflammation. Reported in a substantial proportion of patients and frequently unrecognised, because people do not connect sore eyes with facial redness.
More than one subtype is often present at once. The plan follows what is actually there, not the label.
The trigger list is consistent across populations: heat, sun exposure, alcohol, spicy food, emotional stress, hot drinks.
Look at the first two. Singapore sits one degree off the equator. Ambient heat is constant, and UV is high year-round — through cloud, through car windows, walking to lunch. Neither is avoidable the way a glass of red wine is.
Which changes the emphasis. Where trigger avoidance carries a plan in a temperate climate, here more of the work goes into reducing the inflammatory baseline so that unavoidable triggers produce a smaller response. Daily sunscreen is not an afterthought in this condition — it is part of the treatment.
Barrier dysfunction is part of rosacea rather than incidental to it. So the instinct that helps with acne actively harms here.
Aggressive exfoliation, high-strength actives, stripping cleansers, scrubs, and layered treatment products all disrupt a barrier that is already compromised. People often escalate precisely because nothing is working — and the escalation is what keeps it going.
The same applies to energy-based treatment. Heat is a trigger. Aggressive settings in a condition defined partly by vascular reactivity can provoke rather than settle it, which is why conservative parameters matter more here than device choice.
Rosacea has an inflammatory component and a vascular one, and they are addressed differently.
Approaches directed at inflammatory activity act on the process rather than only on its visible result — upstream rather than downstream. R2 Glow uses long-pulsed 755 nm and 1064 nm directed at inflammatory activity within the skin, and it is what is generally reached for first where redness is diffuse and the picture is inflammatory.
Where telangiectasia is established — individual visible vessels rather than general flush — the vessels themselves are a separate target, and that is assessed on its own terms.
Where the picture includes textural change and background redness together, 675 nm reaches the reticular dermis at 2–3 mm and is absorbed by collagen rather than by water, which makes it relevant to the vascular and structural elements at once.
Topical and oral medical management remains central, and some agents require assessment and monitoring before any course begins.
Response varies with subtype, duration, skin type and previous treatment. Rosacea is chronic and relapsing; management aims at reducing activity and lengthening intervals between flares rather than at cure. Suitability is assessed in person.
Rosacea is managed, not cured. Anyone describing permanent clearance is describing something other than rosacea.
What is realistic is a lower inflammatory baseline, fewer and shorter flares, and a face that is less reactive to the things that cannot be avoided in this climate. For most patients that is the difference that matters day to day.
No. Sensitive skin describes a reactivity to products or environment. Rosacea is a chronic inflammatory condition of the facial skin involving the blood vessels and the immune response, with a characteristic distribution across the central face. Treating rosacea as though it were product sensitivity leads people to cycle through gentler and gentler skincare while the underlying inflammation continues.
Erythematotelangiectatic, characterised by persistent central facial redness and visible vessels. Papulopustular, with inflammatory papules and pustules that are frequently mistaken for acne. Phymatous, involving thickening of the skin, most often at the nose. And ocular, affecting the eyes with dryness, grittiness and irritation. More than one subtype can be present at once, and they do not respond identically.
Heat is one of the most consistently reported triggers, and ambient temperature and humidity here are high year-round. Sun exposure is a second major trigger and UV is high throughout the year. Neither is avoidable in the way a dietary trigger might be, which is why management here often focuses more on reducing the inflammatory baseline than on trigger avoidance alone.
Rosacea is chronic and relapsing. It is managed rather than cured, and any honest discussion says so at the start. Treatment is directed at reducing inflammatory activity, addressing visible vessels, and lengthening the intervals between flares. Ongoing management is usually part of the plan.
The papulopustular subtype produces inflammatory papules and pustules that look like acne to most people, including some clinicians. The distinguishing features are the absence of comedones, the central facial distribution, and the background erythema. Treating it as acne with aggressive drying agents typically makes the barrier dysfunction worse.
Rosacea involves both an inflammatory component and a vascular one. Approaches directed at inflammatory activity in the skin act on the process rather than only on the visible result. Where telangiectasia is established, the vessels themselves are a separate target. Which applies, and in what order, is decided by examination rather than by subtype label alone.
Barrier support matters, because barrier dysfunction is part of the picture rather than incidental to it. What reliably makes rosacea worse is the opposite approach: aggressive exfoliation, high-strength actives and stripping cleansers. Beyond that, skincare supports management rather than replacing it.
Phymatous change involves thickening of the skin and enlargement of the sebaceous glands, most commonly at the nose. It develops gradually and is more common in men. If you have noticed textural thickening rather than only colour change, that is worth raising at assessment, because it is managed differently from the erythematous subtypes.
Rosacea — StatPearls. National Center for Biotechnology Information. source
Consultations by appointment at Orchard Road, Singapore.
WhatsApp +65 8023 7170 →